- Discuss the potential role of adjuvant treatment with immune checkpoint inhibitors in renal cell carcinoma
- Identify the use of radioligands in the treatment of metastatic prostate cancer
- Apply expanding landscape of targetable alterations and novel targeted therapies in metastatic NSCLC to clinical practice
- Explain new advances in adjuvant/neoadjuvant therapy in early-stage NSCLC
This session will be VIRTUAL ONLY. This means the lecture hall will NOT be open.
Zoom info:
Join from a PC, Mac, iPad, iPhone or Android device:
Please click this URL to join. https://uwmadison.zoom.us/s/96952453000?pwd=UWhtQStlMnlvTEFyckZzTXQ4QzZidz09
Passcode: UWCCC
Description: Presenters, please use the link that zoom sends you and don't forward to anyone else. Thank you!
Or One tap mobile:
+19292056099,,96952453000# US (New York)
+13017158592,,96952453000# US (Washington DC)
Or join by phone:
Dial(for higher quality, dial a number based on your current location):
US: +1 929 205 6099 or +1 301 715 8592 or +1 312 626 6799 or +1 669 900 6833 or +1 253 215 8782 or +1 346 248 7799
Webinar ID: 969 5245 3000
International numbers available: https://uwmadison.zoom.us/u/ad7M1m0CiT
- 1.00 ACPE Contact Hours - Pharmacist
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC Contact Hours
- 1.00 University of Wisconsin–Madison Continuing Education Hours
- 1.00 Approved for AMA PRA Category 1 Credit™